Advertisement
ADVANCED SEARCH

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wright, J. M. Search for Related Content PubMed PubMed Citation Articles by Wright, J. M. Related Collections Drugs: gastrointestinal system Related Article

The double-edged sword of COX-2 selective NSAIDs

Dr. Wright is with the Departments of Pharmacology and Therapeutics and of Medicine, University of British Columbia, Vancouver Hospital, UBC site, Vancouver, BC

Correspondence to: Dr. James M. Wright, Department of Pharmacology and Therapeutics, 2176 Health Sciences Mall, Vancouver BC V6T 1Z3; fax 604 822-0701; jmwright{at}interchange.ubc.ca

Abstract

THE LAUNCH OF THE CYCLOOXYGENASE-2 (COX-2) selective NSAIDs was based on 2 hypotheses: (1) the major adverse effects limiting the usefulness of nonselective NSAIDs are gastrointestinal in nature and (2) COX-2 selective NSAIDs are associated with fewer gastrointestinal adverse effects than nonselective NSAIDs. At the time of the launch, neither of these hypotheses had been proven and, as documented in this review, both remain uncertain. The increased incidence of total and nongastrointestinal serious adverse events, with the COX-2 selective NSAIDs as compared with nonselective NSAIDs, in the Celecoxib Long-term Arthritis Safety Study (CLASS) and the Vioxx Gastrointestinal Outcomes Research (VIGOR) study remains a major concern. The increased morbidity associated with the COX-2 selective NSAIDs may be a manifestation of the COX-2 selectivity of rofecoxib and celecoxib or the supramaximal doses of these drugs used in the trials. Proof that the increased harm was not caused by the COX-2 selectivity of the drugs depends on demonstration in a randomized controlled trial that COX-2 selective NSAIDs at usual doses are as effective as nonselective NSAIDs and cause fewer gastrointestinal serious adverse events without increasing the incidence of total nongastrointestinal serious adverse events.

This article has been cited by other articles:

				P. B. Anning, B. Coles, J. Morton, H. Wang, J. Uddin, J. D. Morrow, S. K. Dey, L. J. Marnett, and V. B. O'Donnell Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors Blood, December 15, 2006; 108(13): 4059 - 4062. [Abstract] [Full Text] [PDF]

				P. W. Armstrong Balancing the cyclooxygenase portfolio. Can. Med. Assoc. J., May 23, 2006; 174(11): 1581 - 1582. [Full Text] [PDF]

				P Sooriakumaran COX-2 inhibitors and the heart: are all coxibs the same? Postgrad. Med. J., April 1, 2006; 82(966): 242 - 245. [Abstract] [Full Text] [PDF]

				H. R. Ranaivo, J. M. Craft, W. Hu, L. Guo, L. K. Wing, L. J. Van Eldik, and D. M. Watterson Glia as a Therapeutic Target: Selective Suppression of Human Amyloid-beta-Induced Upregulation of Brain Proinflammatory Cytokine Production Attenuates Neurodegeneration J. Neurosci., January 11, 2006; 26(2): 662 - 670. [Abstract] [Full Text] [PDF]

				J. Hippisley-Cox, C. Coupland, and R. Logan Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis BMJ, December 3, 2005; 331(7528): 1310 - 1316. [Abstract] [Full Text] [PDF]

				S. L. Curry, S. M. Cogar, and J. L. Cook Nonsteroidal Antiinflammatory Drugs: A Review J. Am. Anim. Hosp. Assoc., September 1, 2005; 41(5): 298 - 309. [Abstract] [Full Text] [PDF]

				J. Hippisley-Cox and C. Coupland Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis BMJ, June 11, 2005; 330(7504): 1366. [Abstract] [Full Text] [PDF]

				L. E. Levesque, J. M. Brophy, and B. Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults Ann Intern Med, April 5, 2005; 142(7): 481 - 489. [Abstract] [Full Text] [PDF]

				A. Misak Coxib medications to be handled with care Can. Med. Assoc. J., February 1, 2005; 172(3): 330 - 330. [Full Text] [PDF]

				I. J. Chang and R. C. Harris Are All COX-2 Inhibitors Created Equal? Hypertension, February 1, 2005; 45(2): 178 - 180. [Full Text] [PDF]

				J. M. Bjordal, A. E. Ljunggren, A. Klovning, and L. Slordal Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials BMJ, December 4, 2004; 329(7478): 1317. [Abstract] [Full Text] [PDF]

				S. Brien, G. Lewith, A. Walker, S. M. Hicks, and D. Middleton Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies Evid. Based Complement. Altern. Med., December 1, 2004; 1(3): 251 - 257. [Abstract] [Full Text] [PDF]

				S. H. Roth and J. Z. Shainhouse Efficacy and Safety of a Topical Diclofenac Solution (Pennsaid) in the Treatment of Primary Osteoarthritis of the Knee: A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial Arch Intern Med, October 11, 2004; 164(18): 2017 - 2023. [Abstract] [Full Text] [PDF]

				N Nathoo, G H Barnett, and M Golubic The eicosanoid cascade: possible role in gliomas and meningiomas J. Clin. Pathol., January 1, 2004; 57(1): 6 - 13. [Abstract] [Full Text] [PDF]

				J. M. Wright Why don't we initiate more large simple randomized controlled trials? Can. Med. Assoc. J., November 25, 2003; 169(11): 1170 - 1171. [Full Text] [PDF]

				M. R. Pijak and F. Gazdik COX-2 inhibitors and type 4 error Can. Med. Assoc. J., August 5, 2003; 169(3): 190 - 190. [Full Text] [PDF]

				W. P. Maksymowych Seeking disclosure Can. Med. Assoc. J., April 15, 2003; 168(8): 960 - 962. [Full Text] [PDF]

				J. M. Wright Seeking disclosure Can. Med. Assoc. J., April 15, 2003; 168(8): 962 - 962. [Full Text] [PDF]

				POEM: Harms outweigh benefits of COX 2 for many patients BMJ, March 15, 2003; 326(7389): 0 - 0. [Full Text] [PDF]

				L. E. Levesque, J. M. Brophy, and B. Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults Ann Intern Med, April 5, 2005; 142(7): 481 - 489. [Abstract] [Full Text] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2002, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.